83 related articles for article (PubMed ID: 22843883)
1. Screening for cytotoxic compounds in poor-prognostic chronic lymphocytic leukemia.
Norberg M; Lindhagen E; Kanduri M; Rickardson L; Sundström C; Stamatopoulos K; Rosenquist R; Åleskog A
Anticancer Res; 2012 Aug; 32(8):3125-36. PubMed ID: 22843883
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
3. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
[TBL] [Abstract][Full Text] [Related]
4. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
[TBL] [Abstract][Full Text] [Related]
6. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.
Amiel A; Leopold L; Gronich N; Yukla M; Fejgin MD; Lishner M
Cancer Genet Cytogenet; 2006 Jun; 167(2):145-9. PubMed ID: 16737914
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
8. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.
Pallasch CP; Schwamb J; Königs S; Schulz A; Debey S; Kofler D; Schultze JL; Hallek M; Ultsch A; Wendtner CM
Leukemia; 2008 Mar; 22(3):585-92. PubMed ID: 18079738
[TBL] [Abstract][Full Text] [Related]
9. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
[TBL] [Abstract][Full Text] [Related]
10. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
[TBL] [Abstract][Full Text] [Related]
11. LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.
Mowery YM; Weinberg JB; Kennedy MN; Bond KM; Moore JO; Lanasa MC; Gockerman JP; Diehl LF; Pizzo SV; Cianciolo GJ; Friedman DR
Leukemia; 2010 Sep; 24(9):1580-7. PubMed ID: 20613784
[TBL] [Abstract][Full Text] [Related]
12. Genomic aberrations and survival in chronic lymphocytic leukemia.
Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P
N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261
[TBL] [Abstract][Full Text] [Related]
13. High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature.
Janssens A; Van Roy N; Poppe B; Noens L; Philippé J; Speleman F; Offner F
Eur J Haematol; 2012 Jul; 89(1):72-80. PubMed ID: 22509718
[TBL] [Abstract][Full Text] [Related]
14. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.
Zenz T; Döhner H; Stilgenbauer S
Best Pract Res Clin Haematol; 2007 Sep; 20(3):439-53. PubMed ID: 17707832
[TBL] [Abstract][Full Text] [Related]
15. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
17. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia.
Loeder S; Zenz T; Schnaiter A; Mertens D; Winkler D; Döhner H; Debatin KM; Stilgenbauer S; Fulda S
Cancer Res; 2009 Dec; 69(23):8977-86. PubMed ID: 19920200
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
19. Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.
Opel D; Schnaiter A; Dodier D; Jovanovic M; Gerhardinger A; Idler I; Mertens D; Bullinger L; Stilgenbauer S; Fulda S
Int J Cancer; 2015 Dec; 137(12):2959-70. PubMed ID: 26096065
[TBL] [Abstract][Full Text] [Related]
20. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis.
Frenzel LP; Patz M; Pallasch CP; Brinker R; Claasen J; Schulz A; Hallek M; Kashkar H; Wendtner CM
Br J Haematol; 2011 Jan; 152(2):191-200. PubMed ID: 21091905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
